Novo-Nordisk A/S (NVO) News
Latest headlines that mention NVO, newest first · each headline opens the original publisher
- Last price
- $38.18
- Day change
- -0.21%
- Next earnings
- 2026-11-04
NVO headlines
last 30 daysNovo Nordisk has a huge opportunity in GLP-1 weight-loss drugs, but it has to prove it can use that success to build for the future.
Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.
Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.
The company's search for its next wave of billion-dollar drugs continues.
Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.
Roche is increasingly looking like a notable contender in this fast-growing area.
Management is forecasting a considerable slowdown in its revenue growth.
Novo Nordisk said Tuesday the company struck its second licensing deal since it received a poor reception from investors after presenting its long-term strategy.
Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.
The drugmaker badly needs more clinical wins.
Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.
Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.
CEO Mike Doustdar spoke openly about a risk facing Wegovy and Ozempic, and Wall Street's growth expectations for Novo shifted quickly.
As Medicare Bridge participation surges, Novo Nordisk's share of those new patients is drawing attention.
The U.S. now accounts for more than half of Novo Nordisk’s revenue.
Also mentioned with NVO
30dHeadlines that tag both tickers
NVO news alerts
Get an alert by email or push when a new headline mentions NVO.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.